To clarify the role of donor leukocyte infusion (DLI) in the treatment of leukemia relapsing
after allo-BMT, data from 100 patients were collected from 46 facilities in Japan and …

To clarify the role of dose escalation of donor leukocyte infusion (DLI) in the treatment of
relapsed leukemia after allogeneic bone marrow transplant (BMT), data from 100 patients …

Because the efficacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML)
relapse after allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain …

Purpose: Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may
attain complete remissions when treated with transfusions of leukocytes obtained from the …

The efficacy and toxicity of donor leukocyte infusions (DLI) after unrelated donor bone
marrow transplantation (BMT) is largely unknown. We identified 58 recipients of unrelated …

Abstract Between 1991 and 1999, 44 leukemic patients received donor lymphocyte
infusions (DLIs) at our center (22 patients with chronic myelogenous leukemia [CML]; 10 …

Donor lymphocyte infusions (DLI) were given between June 1990 and March 1996 to 18
patients with chronic myeloid leukemia (CML) for the treatment of cytogenetic (n= 6) or …

To evaluate the safety and efficacy of donor lymphocyte infusion (DLI), we retrospectively
analyzed 414 recipients who received unrelated DLI (UDLI) for the treatment of relapsed …

PURPOSE Treatment options for patients with chronic myeloid leukemia (CML) who relapse
after allogeneic bone marrow transplantation (BMT) are limited. Treatment with lymphocytes …

Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell
transplantation (HSCT). In this retrospective study, 23 patients [15 (65.2%) AML, eight …